FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:817-819 September 12, 1996 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Stanley, S. K. PubMed Citation

To the Editor: Stanley et al. (May 9 issue)¹ report that a booster dose of tetanus toxoid increases the expression of human immunodeficiency virus type 1 (HIV-1) in HIV-1–infected subjects. We have observed the effect of tetanus-toxoid boosters on five untreated, healthy carriers of HIV-1 with stable CD4 counts above 500 per cubic millimeter and on four HIV-negative controls. Data were evaluated on days 0, 7, and 30. The IgG response was always lower in HIV-1 carriers than in controls (mean, 1.4±0.6 IU vs. 20±1.7 IU). The proliferative responses to tetanus toxoid and pokeweed mitogen were also lower in HIV-1 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pirofski, L.-a., Casadevall, A. (1998). Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host. Clin. Microbiol. Rev. 11: 1-26 [Abstract] [Full Text]